论文部分内容阅读
目的 评价诺维本 (navelbine ,NVB)与顺铂 (cisplatin ,DDP)联合治疗非小细胞肺癌 (non smallcelllungcancer ,NSCLC)的疗效及毒副反应。方法 自 1994年 4月至 1998年 12月对 90例中晚期NSCLC患者进行NVB +DDP联合化疗 ,第 1、8天用NVB 2 5～ 3 0mg/m2 ,第 3天用DDP 60～ 80mg/m2 ,每 2 8天为一周期 ,每例患者至少完成 2周期化疗方可评价疗效。结果 全组总有效率为 2 7.8% ( 2 5 /90 ) ,其中Ⅲ期患者总有效率为 41.0 % ( 16/3 9) ,而Ⅳ期有效率仅为 16.5 % ( 8/48) ,两组间有显著性差异 (P <0 .0 0 5 )。本方案主要的副反应是白细胞降低和静脉炎 ,Ⅲ和Ⅳ度白细胞降低发生率分别为 2 0 %和18.9% ,静脉炎发生率为 3 2 .2 % ( 2 9/90 )。通过G CSF的辅助治疗 ,本组无一例因重度骨髓抑制而危及生命 ,而改变NVB的给药方法可减少静脉炎的发生率。结论 NVB +DDP方案治疗NSCLC有较好的疗效 ,白细胞降低是其主要的剂量限制性毒性。
Objective To evaluate the curative effect and toxicity of navelbine (NVB) combined with cisplatin (DDP) on non small cell lung cancer (NSCLC). Methods From April 1994 to December 1998, 90 patients with advanced non-small cell lung cancer (NSCLC) underwent combined NVB + DDP chemotherapy with NVB 2.5-3.0 mg / m 2 on days 1 and 8. DDP 60-80 mg / m 2 on day 3 , Every 28 days for a cycle, each patient completed at least 2 cycles of chemotherapy before evaluation of the effect. Results The total effective rate was 2 7.8% (25/90). The total effective rate in stage Ⅲ was 41.0% (16/3 9), while the effective rate in stage Ⅳ was only 16.5% (8/48) There was a significant difference between groups (P <0.05). The main side effects of this program is leukopenia and phlebitis, Ⅲ and Ⅳ grade leukopenia incidence rates were 20% and 18.9%, phlebitis incidence was 32.2% (29/90). With the adjuvant treatment of G CSF, none of the patients in this group were life-threatening due to severe myelosuppression, while changing NVB administration reduced the incidence of phlebitis. Conclusions The NVB + DDP regimen has a good curative effect in the treatment of NSCLC. Leukopenia is the main dose-limiting toxicity.